TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14994324

Group type: EXPERIMENTAL
Intervention: Lormetazepam oral solution
Number of subjects: 108

Group type: COMPARATOR
Intervention: Lormetazepam tablets
Number of subjects: 108
Study: 11488780

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no omeprazole)
Number of subjects: 18
Study: 10197085

Group type: EXPERIMENTAL
Intervention: hGH therapy (0.125U/kg/wk increasing to 0.25U/kg/wk)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: hGH therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7908246

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (12 micrograms)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Inhaled salbutamol (200 micrograms)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 4042528

Group type: EXPERIMENTAL
Intervention: 8 mg nicotine base in a 30% aqueous solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inactive placebo solution
Number of subjects: 10
Study: 30883188

Group type: EXPERIMENTAL
Intervention: Conventional loading after a 12-week healing period
Number of subjects: 32

Group type: COMPARATOR
Intervention: Immediate loading within one week after insertion
Number of subjects: 32
Study: 28965648

Group type: EXPERIMENTAL
Intervention: Immediate-release oxycodone with supportive strategies
Number of subjects: 122

Group type: COMPARATOR
Intervention: Controlled-release oxycodone
Number of subjects: 122
Study: 27052743

Group type: EXPERIMENTAL
Intervention: Autologous CIK cell immunotherapy in combination with chemotherapy (FOLFOX4 plan)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Chemotherapy (FOLFOX4 plan) alone
Number of subjects: 122
Study: 25461784

Group type: EXPERIMENTAL
Intervention: Technician-administered internet cognitive behaviour therapy (iCBT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 67
Study: 22956251

Group type: EXPERIMENTAL
Intervention: VBLOC® Therapy (vagal blockade)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Control group (no vagal blockade)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: VBLOC® Therapy (vagal blockade) with ≥ 12 h/day use
Number of subjects: 503

Group type: COMPARATOR
Intervention: Control group with ≥ 12 h/day use
Number of subjects: 503
Study: 20202489

Group type: EXPERIMENTAL
Intervention: naproxcinod 375 mg
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg
Number of subjects: 918

Group type: COMPARATOR
Intervention: naproxen 500 mg
Number of subjects: 918

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 918
Study: 17967821

Group type: EXPERIMENTAL
Intervention: Early CPAP (CPAP alone for 15 min)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Late CPAP (CPAP added to medical treatment for 15 min)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Early CPAP
Number of subjects: 124

Group type: COMPARATOR
Intervention: Late CPAP
Number of subjects: 124
Study: 17283268

Group type: EXPERIMENTAL
Intervention: Radial artery grafts
Number of subjects: 880

Group type: COMPARATOR
Intervention: Saphenous vein grafts
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 880
Study: 14967728

Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg
Number of subjects: 3717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3717
Study: 11035317

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 8638755

Group type: EXPERIMENTAL
Intervention: Standard physical therapy program with patellar taping
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard physical therapy program without patellar taping
Number of subjects: 25
Study: 1483075

Group type: EXPERIMENTAL
Intervention: Coordination group with nurse coordinators
Number of subjects: 554

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 554
Study: 4048835

Group type: EXPERIMENTAL
Intervention: Fat (50 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Protein (50 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Starch (50 g)
Number of subjects: 8
Study: 31204114

Group type: EXPERIMENTAL
Intervention: DMPA‐IM (150 mg/mL every 3 months)
Number of subjects: 7830

Group type: EXPERIMENTAL
Intervention: Copper IUD
Number of subjects: 7830

Group type: EXPERIMENTAL
Intervention: LNG implant
Number of subjects: 7830

Group type: EXPERIMENTAL
Intervention: DMPA‐IM
Number of subjects: 7830
Study: 28683283

Group type: EXPERIMENTAL
Intervention: Amlexanox
Number of subjects: 42
Study: 26118815

Group type: EXPERIMENTAL
Intervention: Guided self-help program for parents of children with ADHD (1 year duration, 8 booklets, 14 telephone consultations up to 20 minutes each)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Guided self-help program for parents of children with ADHD
Number of subjects: 274
Study: 23044388

Group type: EXPERIMENTAL
Intervention: NTP treated for 10s with sand-blasting (SB)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NTP treated for 10s with Clearfil ceramic primer (MDP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NTP treated for 10s with sand-blasting+MDP (SBMDP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NTP treated for 10s with baseline (B)
Number of subjects: 24
Study: 21545459

Group type: EXPERIMENTAL
Intervention: Self-focused rumination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provocation-focused rumination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both types of rumination
Number of subjects: 0
Study: 19701647

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 17669768

Group type: EXPERIMENTAL
Intervention: Swine gelatin plus rifamycin
Number of subjects: 557

Group type: COMPARATOR
Intervention: Bone wax
Number of subjects: 557
Study: 15194131

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg as a single shot
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 200 mg once daily for 3 days
Number of subjects: 741

Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg twice daily for 3 days
Number of subjects: 741
Study: 11707763

Group type: EXPERIMENTAL
Intervention: Word-only descriptions of stool consistency classifications
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Word + diagram descriptions of stool consistency classifications
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Subjects' classifications on days 1 and 2
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Subjects' classifications compared with investigators
Number of subjects: 103
Study: 9158269

Group type: EXPERIMENTAL
Intervention: Promethazine hydrochloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lignocaine hydrochloride
Number of subjects: 20
Study: 8424511

Group type: EXPERIMENTAL
Intervention: 5 mg of morphine in 25 mL of saline (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 25 mL of 0.25% bupivacaine (62.5 mg) (Group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of 5 mg of morphine and 62.5 mg of bupivacaine in 25 mL dilution (Group 3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 25 mL of saline (Group 4)
Number of subjects: 40
Study: 3318543

Group type: EXPERIMENTAL
Intervention: Ketamine 4 micrograms/kg/minute
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine 33 micrograms/minute
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 60
Study: 29161166

Group type: EXPERIMENTAL
Intervention: Intervention group (motivational element, quitting preparation components, pre-quit nicotine patch)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (attention control)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 222
Study: 27480840

Group type: EXPERIMENTAL
Intervention: Alogliptin with ACE inhibitor
Number of subjects: 3323

Group type: COMPARATOR
Intervention: Placebo with ACE inhibitor
Number of subjects: 3323

Group type: EXPERIMENTAL
Intervention: Alogliptin without ACE inhibitor
Number of subjects: 3323

Group type: COMPARATOR
Intervention: Placebo without ACE inhibitor
Number of subjects: 3323

Group type: EXPERIMENTAL
Intervention: Higher doses of ACE inhibitor
Number of subjects: 3323
Study: 24864326

Group type: EXPERIMENTAL
Intervention: Bimanual microincision cataract surgery (MICS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2.2-mm coaxial phacoemulsification
Number of subjects: 50
Study: 21195430

Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (EST)
Number of subjects: 211
Study: 20045571

Group type: EXPERIMENTAL
Intervention: Ophthalmologists classifying optic disc photographs
Number of subjects: 243

Group type: COMPARATOR
Intervention: GDx‐VCC nerve fiber indicator
Number of subjects: 243

Group type: COMPARATOR
Intervention: HRT's best classifier
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement (kappa)
Number of subjects: 243
Study: 18287833

Group type: EXPERIMENTAL
Intervention: Cold needle
Number of subjects: 80

Group type: COMPARATOR
Intervention: Room temperature needle
Number of subjects: 80
Study: 16158688

Group type: EXPERIMENTAL
Intervention: Activity-based intervention (15 weeks, 3 times a week, 30 minutes each session)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Direct instruction (15 weeks, 3 times a week, 30 minutes each session)
Number of subjects: 2
Study: 11912360

Group type: EXPERIMENTAL
Intervention: 0.5% tranilast eye drops
Number of subjects: 52

Group type: COMPARATOR
Intervention: Vehicle saline solution
Number of subjects: 52
Study: 9707351

Group type: EXPERIMENTAL
Intervention: (R)-propranolol 80 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (S)-propranolol 80 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rac-propranolol 160 mg
Number of subjects: 15
Study: 8520187

Group type: EXPERIMENTAL
Intervention: 200‐mg vaginal progesterone suppositories
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 1669270

Group type: EXPERIMENTAL
Intervention: Immunotherapy in A Group (10 patients)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group B (11 patients)
Number of subjects: 21
Study: 308357

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (selective)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nonselective shunting procedures
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Portal flow (selective and nonselective)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Continuing portal perfusion
Number of subjects: 55
Study: 31593588

Group type: EXPERIMENTAL
Intervention: CMV gB/MF59 vaccine
Number of subjects: 15
Study: 31409568

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation + lyso-thermosensitive liposomal doxorubicin (LTLD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiofrequency ablation only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups analyzed for BPV effect
Number of subjects: 0
Study: 28131322

Group type: EXPERIMENTAL
Intervention: Dalfampridine extended release (D-ER) 10 mg BID
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25501294

Group type: EXPERIMENTAL
Intervention: 5 mg zopiclone
Number of subjects: 31
Study: 23242595

Group type: EXPERIMENTAL
Intervention: Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance
Number of subjects: 459
Study: 21333385

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin infusion without nasogastric tube placement (erythromycin group)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Nasogastric tube placement without erythromycin (nasogastric group)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin infusion combined with nasogastric tube placement (nasogastric-erythromycin group)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 253
Study: 19892392

Group type: EXPERIMENTAL
Intervention: Early treatment (Oportunidades programme for 18 months earlier)
Number of subjects: 1793

Group type: COMPARATOR
Intervention: Late treatment (Oportunidades programme started 18 months later)
Number of subjects: 1793

Group type: EXPERIMENTAL
Intervention: Additional 18 months in the Oportunidades programme for children whose mothers had no education
Number of subjects: 1793
Study: 16881772

Group type: EXPERIMENTAL
Intervention: Combination of medication management and intensive behavior therapy (Comb)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Medication management (MedMgt)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Community-treated comparison (CC)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Intensive behavior therapy
Number of subjects: 579
Study: 15701190

Group type: EXPERIMENTAL
Intervention: Blocked drain and ropivacaine
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Patent drain and ropivacaine
Number of subjects: 128

Group type: COMPARATOR
Intervention: Blocked drain and saline
Number of subjects: 128

Group type: COMPARATOR
Intervention: Patent drain and saline
Number of subjects: 128
Study: 11339912

Group type: EXPERIMENTAL
Intervention: Polymorphism of interleukin‐1 receptor antagonist gene
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Three mutant alleles of interleukin‐1 beta and interleukin‐1 receptor antagonist genes
Number of subjects: 116
Study: 9198829

Group type: EXPERIMENTAL
Intervention: Thyroxin treatment (started on average 5 years after surgery)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Thyroxin treatment (permanently treated)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (not treated with thyroxin, average 2 years after surgery)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Thyroxin treatment (in patients with nodular regrowth)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Thyroxin treatment (in patients with high serum TSH concentrations)
Number of subjects: 228
Study: 1586270

Group type: EXPERIMENTAL
Intervention: Haloperidol low dose (2 to 13 ng/mL)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Haloperidol medium dose (13.1 to 24 ng/mL)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Haloperidol high dose (24.1 to 35 ng/mL)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (single-blind period)
Number of subjects: 176
Study: 3894872

Group type: EXPERIMENTAL
Intervention: Caffeine solution (5 mg X kg‐1 body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electrolyte‐glucose solution (ERG)
Number of subjects: 10
Study: 31023257

Group type: EXPERIMENTAL
Intervention: AferBio®
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 10
Study: 28423480

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (20,000 IU)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Standard-dose vitamin D3 (800 IU)
Number of subjects: 297
Study: 25567822

Group type: COMPARATOR
Intervention: Personalized mailed letters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Automated telephone calls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined (letter/automated call)
Number of subjects: 0
Study: 23485070

Group type: EXPERIMENTAL
Intervention: Tourniquet cuff pressure of 237 (SD 33) mmHg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low tourniquet cuff pressures
Number of subjects: 20
Study: 21518220

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) 200 mg twice daily or 400 mg once daily combined with tenofovir 300 mg/emtricitabine 200 mg once daily
Number of subjects: 569

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily combined with tenofovir 300 mg/emtricitabine 200 mg once daily
Number of subjects: 569
Study: 18350281

Group type: EXPERIMENTAL
Intervention: 333 mg Salvia extract
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 167 mg Salvia extract
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 666 mg Salvia extract
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1332 mg Salvia extract
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17068306

Group type: EXPERIMENTAL
Intervention: rt-PA (intravenous recombinant tissue plasminogen activator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional inclusion criteria
Number of subjects: 0
Study: 14535908

Group type: EXPERIMENTAL
Intervention: Remifentanil (loading dose 1 microg x kg(‐1); maintenance infusion, 0.25 microg x kg(‐1) min(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alfentanil (loading dose 50 microg x kg(‐1); maintenance infusion, 1 microg x kg(‐1) min(‐1))
Number of subjects: 60
Study: 11075771

Group type: EXPERIMENTAL
Intervention: ALM plus BCG
Number of subjects: 2306

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 2306
Study: 8838433

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily (increased to 10 mg if necessary)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg twice daily (increased to 180 mg if necessary)
Number of subjects: 34
Study: 1442589

Group type: COMPARATOR
Intervention: Dietary fish oil
Number of subjects: 8
Study: 3900155

Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 3% topical minoxidil
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (initially) then crossed over to 3% topical minoxidil
Number of subjects: 126
Study: 3793950

Group type: COMPARATOR
Intervention: Conventional quinidine sulfate 300 mg q6h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sustained-release quinidine sulfate 600 mg q12h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sustained-release quinidine gluconate 648 mg q12h
Number of subjects: 18
Study: 29737513

Group type: EXPERIMENTAL
Intervention: Intraoperative complications
Number of subjects: 2856

Group type: EXPERIMENTAL
Intervention: Predictive model for intraoperative complications
Number of subjects: 2856
Study: 28322009

Group type: EXPERIMENTAL
Intervention: Worse left ventricular mechanical dyssynchrony (measured by SD T2P LS)
Number of subjects: 424
Study: 26315829

Group type: EXPERIMENTAL
Intervention: 177Lu-EDTMP
Number of subjects: 32

Group type: COMPARATOR
Intervention: 153Sm-EDTMP
Number of subjects: 32
Study: 22593231

Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 30
Study: 21195290

Group type: EXPERIMENTAL
Intervention: Electroacupuncture on the point Sanyinjiao (SP6)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 350
Study: 18400351

Group type: EXPERIMENTAL
Intervention: Bilateral motor activations of the approach and avoidance motivational systems
Number of subjects: 0
Study: 16817580

Group type: EXPERIMENTAL
Intervention: Daily activities (sitting, walking, running, jumping jacks, vertical leap, jumping off a step)
Number of subjects: 18
Study: 14570661

Group type: EXPERIMENTAL
Intervention: Epidural bolus administration of fentanyl (0.03 mg followed by 0.1 mg 210 min later)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural infusion of fentanyl (0.03 mg/h followed by 0.1 mg/hr 210 min later for 200 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural infusion of fentanyl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural bolus administration of fentanyl
Number of subjects: 10
Study: 10894961

Group type: EXPERIMENTAL
Intervention: Daily repeated applications of moisturizers (twice daily for 5 days)
Number of subjects: 0
Study: 8669676

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 351
Study: 1563339

Group type: EXPERIMENTAL
Intervention: Neurotol slow
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tegretol Retard
Number of subjects: 21
Study: 4004715

Group type: EXPERIMENTAL
Intervention: Weight-loss treatment groups defined by homogeneity (similar gender and degree of overweight)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Weight-loss treatment groups defined by heterogeneity (dissimilar gender and degree of overweight)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Participants with prior unsuccessful weight-loss experiences
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Heavier individuals
Number of subjects: 139
Study: 31699516

Group type: EXPERIMENTAL
Intervention: Second generation antipsychotics (AP); 92% of patients received this intervention; 74% received AP monotherapy; 79.5% received off-label AP prescriptions.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: First 3 months of treatment; noted as a significant period for AEs.
Number of subjects: 200
Study: 28203808

Group type: EXPERIMENTAL
Intervention: Shamrock LPB
Number of subjects: 20

Group type: COMPARATOR
Intervention: LUT LPB
Number of subjects: 20
Study: 25863847

Group type: EXPERIMENTAL
Intervention: SF6 gas tamponade
Number of subjects: 59

Group type: COMPARATOR
Intervention: C3F8 gas tamponade
Number of subjects: 59
Study: 24048091

Group type: EXPERIMENTAL
Intervention: Local vancomycin powder in addition to systemic prophylaxis
Number of subjects: 907

Group type: COMPARATOR
Intervention: Standard systemic prophylaxis only (Control)
Number of subjects: 907
Study: 20837824

Group type: EXPERIMENTAL
Intervention: Pioglitazone (Actos), 45 mg daily, plus 200 IU of vitamin E daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo, plus 200 IU of vitamin E daily
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pioglitazone (Actos)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 18952945

Group type: EXPERIMENTAL
Intervention: Non-interruptive medication laboratory alerts
Number of subjects: 366

Group type: COMPARATOR
Intervention: Existing system (control group)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 366
Study: 17196292

Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field (PEMF) therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Spa Therapy (ST)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 80
Study: 15471838

Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20